Primary Recipient

UNIVERSITY OF ALABAMA AT BIRMINGHAM

Amount

$146,458.00

Award Date

7/17/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

Currently 5FU/LV/oxaliplatin (FOLFOX) is the most commonly used therapeutic agent for colorectal cancer (CRC) treatment (Rx). The anti-tumor activity of FOLFOX depends on its ability to induce apoptosis by damaging the DNA and by altering the expression o